Profit margins, US medicine supplies may get hit: Biocon
BENGALURU: Biocon is gearing up to manage potential challenges arising from US govt’s proposed tariffs on pharma imports. The company cautioned that these higher duties could impact profit margins and disrupt the availability of affordable generic medicines for American patients.The US remains Biocon’s largest market, contributing a significant share of its overall sales. However, the…
